|Mr. Eric A. Adams||Pres, CEO & Director||504.6k||N/A||1963|
|Dr. Eric Chih-Hsien Hsu||Sr. VP of Preclinical R&D||294.01k||N/A||N/A|
|Mr. Jeffrey M. Charpentier||VP of Fin. & Corp. Sec.||282.89k||N/A||N/A|
|Dr. Sazzad Hossain||Co-Founder & Member of the Scientific Advisory Board||N/A||N/A||N/A|
|Mr. Bruce S. Colwill C.A., CPA, CA||Chief Financial Officer||N/A||N/A||N/A|
InMed Pharmaceuticals Inc., a pre-clinical stage biopharmaceutical company, researches and develops cannabinoid-based therapies. The company's lead product is INM-755, a cannabinoid product candidate to treat epidermolysis bullosa. The company is also involved in developing INM-085, a cannabinoid-based topical therapy for glaucoma; and INM-405 for the treatment of orofacial pain. In addition, it engages in the development of drugs for the treatment of various diseases, including dermatology, ocular, pain, inflammation, pulmonary disease, neurodegenerative, and oncology disease areas. It has an agreement with Pharmaseed Ltd to develop a final formulation for INM-755; and work on IND-enabling pharmacology and toxicology studies. The company also has research agreement with the National Research Council of Canada in for biofermentation development and scale-up processes for cannabinoid biosynthesis in E.coli. The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014. InMed Pharmaceuticals Inc. was incorporated in 1981 and is headquartered in Vancouver, Canada.
InMed Pharmaceuticals Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.